ROS1 and non-small cell lung carcinoma: Noticeable, even in the smallest cohorts of the ALK/ROS and EGFR inhibitors alectinib, crizotinib and osimertinib, which are approved for NSCLC, we were able to find patients with highly increased sensitivity to radiation in PBMCs which should lead to a certain attention.